• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
GYN
CMECNE

Prescribing Flibanserin for Low Desire: How, When and Where?

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Identify the appropriate candidate and use for the drug
2. Explain those steps needed to prescribe the medication

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from Dec 31 2017 through Jan 25 2023, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Designated for 0.2 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Read Disclaimer & Fine Print

CLINICAL ACTIONS:

Medical treatment is available for low sexual desire (HSDD). Typically, a general physical examination, CBC and chemistry panel can ensure that the low libido is not a symptom of a more significant medical problem.

    • Depression screening should be performed
    • Rule out general medical illnesses or surgical causes
    • Differentiate low desire, the indication for this medication, from low arousal
    • Flibanserin can be given concomitantly with hormone treatment

SYNOPSIS:

Flibanserin has been shown to increase sexual desire in women. Any prescription of flibanserin should follow a thorough history-taking evaluation. Management often requires a multimodal approach and therefore consistency and efficacy may be improved with associated behavioral therapy.

KEY POINTS:

    • Obtain a thorough history and evaluation in order to diagnose low libido
    • Daily dosage is 100 mg daily and should be taken before bed as it can make patients drowsy
    •  The black box FDA warning was changed (October 2019)
      • Alcohol is no longer a contraindication
      • Risk Evaluation and Mitigation Strategy (REMS) distribution restrictions have been removed
    • Consider registering to receive drug company coupons when available, as the drug may be prohibitively expensive without them
    • Concomitant behavioral and psychotherapy can be extremely helpful in the process
  • Concomitant behavioral therapy and psychotherapy may be helpful in the process
    • Consider simultaneous referral to sex therapist while treating the patient
  • Diagnosis Codes: Sexual interest/arousal disorder: DSM-5 302.72 (F52.22)

Adverse Events

  • Although alcohol is not contraindicated, patients should be made aware that
    • Flibanserin and alcohol increases the risk of severe hypotension and syncope
    • Women should discontinue drinking alcohol at least two hours before taking flibanserin at bedtime or to skip the flibanserin dose that evening
    • If ingesting 3 or more drinks, dose should be skipped that evening
    • Women should not consume alcohol at least until the morning after taking flibanserin at bedtime
  • Flibanserin is contraindicated in patients with hepatic impairment or using strong or moderate CYP3A4 inhibitors (list of contraindicated medications can be found in the ‘Learn More – Primary Sources’ using the Medication Guide link | Include medications to treat HIV, fungal infections and some antibiotics)
    • Severe hypotension and syncope can occur when  used in these settings
  • Not recommended for use during pregnancy or if breastfeeding

Learn More – Primary Sources:

Flibanserin and Female Sexual Desire

Flibanserin for Treating Hypoactive Sexual Desire Disorder

Flibanserin for hypoactive sexual desire disorder: place in therapy

ISSWSH Expert Consensus Panel Review: Hypoactive Sexual Desire Disorder 

FDA: ADDYI Highlights of Prescribing Information 

FDA: Medication Guide for Addyi 

Locate a Sexual Health Professional:

AASECT-Referral Directory 

ISSWSH-Find a Provider 

SSTAR-Find a Therapist

Take a post-test and get CME credits

TAKE THE POST TEST

Want to be notified when new guidelines are released? Get ObGFirst!

Learn More »

image_pdfFavoriteLoadingFavorite

< Previous
All GYN Posts
Next >

Related ObG Topics:

A Patient Complains of Low Sexual Desire – Making an Accurate Diagnosis
Treatment Options for the Patient with Low Sexual Desire
Testosterone Therapy for Low Desire – How, When and Where?
Practical info on sexual health for your women's healthcare practice
Female Sexual Dysfunction Explained 
Asking About Sexual Health
What is Sex Therapy?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site